GLP-2 Tirzepatide (40mg vials)

Description

Tirzepatide is a synthetic 39-amino-acid peptide with a C20 fatty-diacid moiety that acts as a dual agonist at the GIP and GLP-1 receptors. Peptide Partners supplies Tirzepatide in 40mg vials for laboratory research into dual-incretin receptor pharmacology and biased signaling.

GLP-2 Tirzepatide specifications

Product Format	40mg vials
Vial Size	40mg
Vial Capacity	3 mL
Box Combinations	80mg, 200mg, 400mg, 800mg, 1200mg
Multi-vial Purity	99.705%
Endotoxin Screening	PASSED
Heavy Metals Screening	PASSED
Sterility Screening	PASSED
Independently Tested	YES

Published research on GLP-2 Tirzepatide

The summaries below describe peer-reviewed literature for educational and reference purposes only. They do not describe uses of this product, which is sold for laboratory research only.

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Authors: Willard FS, Douros JD, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, Cardona GR, Urva S, Emmerson PJ, Rosenkilde MM, Campbell JE, Sloop KW
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC7526454/

Pharmacological characterization showed that tirzepatide is an imbalanced dual agonist: full efficacy at GIPR, partial efficacy at GLP-1R with signaling biased toward cAMP over β-arrestin recruitment, and differential receptor internalization. Ex-vivo pancreatic islet experiments and receptor-occupancy estimates were also reported.

Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor

Authors: Ajit Regmi, Eitaro Aihara, Michael E. Christe, Gabor Varga, Thomas P. Beyer, Xiaoping Ruan, Emily Beebe, Libbey S. O’Farrell, Melissa A. Bellinger, Aaron K. Austin, Yanzhu Lin, Haitao Hu, Debra L. Konkol, Samantha Wojnicki, Adrienne K. Holland, Jessica L. Friedrich, Robert A. Brown, Amanda S. Estelle, Hannah S. Badger, Gabriel S. Gaidosh, William Roell
Source: https://www.sciencedirect.com/science/article/pii/S1550413124001864

Using human adipocytes and mouse models, researchers studied long-acting GIP-receptor agonism, measuring insulin signaling, glucose uptake, glycerol conversion, lipolysis, circulating triglycerides during oral lipid challenge and lipoprotein-derived fatty-acid uptake into adipose tissue.

GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress

Authors: Yan Tian, Ruixue Tian, He Juan, Yafan Guo, Pan Yan, Yao Cheng, Rongshan Li, Baodong Wang
Source: https://www.sciencedirect.com/science/article/pii/S1567576924023993

In a mouse diabetic nephropathy model and in high-glucose-exposed podocytes, researchers used transcriptome sequencing, Western blot and immunohistochemistry to examine tirzepatide’s effects on oxidative-stress markers and PI3K/AKT signaling, including reversal by a PI3K inhibitor.

Storage and handling

GLP-2 Tirzepatide is supplied for laboratory use. Store unopened vials cold and protected from light, and follow the storage notes on the vial label. Handle only in an appropriate laboratory setting by qualified personnel.

Research use only

This product is sold solely for in-vitro research and laboratory experimentation. It is not a drug, food, supplement or cosmetic, and is not for human or veterinary use. Information on this page is provided for educational purposes only. Purchasers must be qualified research professionals; see our Terms and Conditions.

Browse more Metabolics research peptides, review our testing standards, or see all research peptides.